MorphoSys (MOR) Earns “Buy” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their buy rating on shares of MorphoSys (ETR:MOR) in a research report sent to investors on Thursday.

MOR has been the topic of several other research reports. Commerzbank set a €107.00 ($124.42) target price on MorphoSys and gave the stock a neutral rating in a research report on Wednesday, August 22nd. Royal Bank of Canada set a €65.00 ($75.58) target price on MorphoSys and gave the stock a sell rating in a research report on Monday, October 1st. Deutsche Bank set a €120.00 ($139.53) target price on MorphoSys and gave the stock a neutral rating in a research report on Monday, August 6th. Oddo Bhf set a €110.00 ($127.91) target price on MorphoSys and gave the stock a buy rating in a research report on Thursday, October 11th. Finally, Berenberg Bank set a €103.00 ($119.77) target price on MorphoSys and gave the stock a buy rating in a research report on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of €96.40 ($112.09).

ETR MOR opened at €94.80 ($110.23) on Thursday. MorphoSys has a 12-month low of €49.63 ($57.71) and a 12-month high of €88.10 ($102.44).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Read More: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply